Karyopharm and menarini group receive positive chmp opinion for nexpovio® (selinexor) for the treatment of patients with refractory multiple myeloma

̶  european commission decision anticipated within approximately 60 days – newton, mass. and florence, italy , may 20, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the menarini group ("menarini"), a privately-held, leading international pharmaceutical company, today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending approval of nexpovio® (selinexor), a first-in-class, oral exportin 1 (xpo1) inhibitor, in combination with once weekly bortezomib (velcade®) and low-dose dexamethasone (svd) for the treatment of adults with multiple myeloma who have received one to three prior lines of therapy.
KPTI Ratings Summary
KPTI Quant Ranking